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Abstract
Introduction: Several in vitro studies have suggested the effects of adipokines and insulin resistance on breast
cancer cell proliferation and survival. However, little is known about the clinical significance of these findings.
Methods: We examined associations between breast cancer recurrence and adiponectin, leptin, insulin resistance,
and metabolic syndrome (MetS) in a cohort of 747 patients from 2001 to 2004.
Results: Adjusted hazard ratios showed an inverse trend across the quartiles for serum adiponectin concentration
in estrogen receptor (ER)/progesterone receptor (PR) -negative patients (P for trend = 0.027) but not in ER/PR-
positive patients. Compared to the highest quartile for adiponectin level, the lowest quartile showed a hazard ratio
of 2.82 (1.03 to 7.68). Homeostasis model assessment for insulin resistance (HOMA-IR) showed a positive trend for
recurrence in the ER/PR-negative group (P for trend = 0.087) and a negative trend in the ER/PR-positive group
(P for trend = 0.081). Leptin did not show any associations (P for trend >0.05). A linear trend was observed with
the number of components of MetS in ER/PR-negative patients (P for trend = 0.044). This association disappeared
when adjusted for adiponectin and HOMA-IR.
Conclusions: Adiponectin and HOMA-IR have prognostic significance in breast cancer recurrence and interventions
related to these factors may protect against recurrence in ER/PR-negative patients. These findings were not
observed in the case of ER/PR-positive patients. Further evaluation of these insignificant associations is needed
because it might be biased by adjuvant chemotherapy or other confounders.
Introduction
Recent studies have suggested that breast cancer is asso-
ciated with insulin resistance [1-5], metabolic syndrome
(MetS) [4,6], and adipokine levels [7-15]. However, the
clinical significance of these findings remains controver-
sial because only limited human data have been pub-
lished, and inconsistent results have been obtained from
these data [1-4,6-16]. Another weakness of previous stu-
dies is that most were conducted under cross-sectional
designs that failed to establish temporal relationships for
causality; in these studies, risk factors were assessed at
the same time or after the study outcomes were
measured.
The evaluation of estrogen receptor (ER) and proges-
terone receptor (PR) expression status in breast cancer
is critical because clinical and biological heterogeneity is
associated with these hormone receptors [17]. Adjuvant
endocrine therapy, such as with tamoxifen or aromatase
inhibitors, is recommended in ER/PR-positive cancer
and significantly improves disease-free and overall survi-
val [18]. However, this adjuvant therapy is not applicable
in ER/PR-negative cancer, which shows a poorer prog-
nosis than ER/PR-positive cancer. Recently, in vitro stu-
dies showed that adiponectin inhibits growth and
enhances apoptosis in an ER-negative breast cancer cell
line [19,20], suggesting that potentiating adiponectin
action may serve as a valuable adjuvant therapy for ER/
PR-negative cancer. However, the clinical significance of
adiponectin remains unclear because of a paucity of
human data.
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tionship between breast cancer recurrence and adipo-
kines, insulin resistance, and MetS. We also investigated
whether these associations may be modified by ER/PR
status and other factors.
Materials and methods
Study participants and follow-up
We studied a cohort of newly diagnosed breast cancer
patients who underwent surgery and consented to pro-
vide blood samples at the National Cancer Center Hos-
pital, Korea, between April 2001 and December 2004.
Among a total of 856 cases considered for the initial
recruitment, 747 patients remained eligible after exclu-
sion for the following: (1) distant metastasis at diagnosis
(8 cases), (2) ductal carcinoma in situ (70 cases), (3)
cancer with unreported ER/PR status (29 cases), (4)
male gender (1 case), and (5) non-epithelial origin of
cancer (1 case of sarcoma).
Breast cancer recurrence included either local recur-
rence or distant metastasis. Informed consents were
obtained from participants. The diagnosis was verified
by reviewing hospital records. In addition, women were
considered to have recurrent disease when the cause of
death was identified as breast cancer. Two patients were
classified as censored cases because their deaths were
not related to breast cancer. This study protocol was
approved by the institutional review board of the
National Cancer Center (IRB Protocol No. NCCNCS-
09-220).
Clinical evaluation and definitions
Data collected in baseline evaluations included data
regarding demographic characteristics, personal and
family medical history, alcohol consumption, smoking
history, number of deliveries, oral contraceptive use,
hormone replacement therapy, breast feeding, and age
at menarche/menopause. Height and weight were
directly measured using a standardized protocol. Body
Mass Index (BMI) was calculated as follows: weight
(kg)/height squared (m
2). Blood pressure was measured
using an automated oscillometric blood pressure device
(Colin BP-8800; Colin Corporation, Hayashi, Japan) after
the subject had rested for five minutes.
We used the definition of MetS as proposed by the
American Heart Association and the National Heart,
Lung, and Blood Institute [21]. These criteria require at
least three of the following components: abdominal obe-
sity, triglycerides ≥150 mg/dl or receiving drug treat-
ment, HDL cholesterol <50 mg/dl for women or
receiving drug treatment, systolic/diastolic blood pres-
sure ≥130/85 mmHg or receiving drug treatment, or
fasting glucose ≥100 mg/dl or receiving drug treatment.
In this study, we used a BMI ≥25 kg/m
2 to define
obesity, because waist circumference was not measured
at the baseline evaluation.
Immunohistochemistry
For the assessment of ER and PR expression status,
immunohistochemical staining was performed using tis-
sue sections cut from formalin-fixed, paraffin-embedded
representative breast tumors. Staining was performed
using the I-View DAB detection kit and a Ventana ES
autostainer (Ventana Medical Systems, Tucson, AZ,
USA) using primary antibodies against ER and PR (both
from Ventana Medical Systems). Specimens were
defined as ER- or PR-positive when nuclear staining was
observed in at least 10% of tumor cells tested [22,23].
Laboratory assessments
Venous blood samples were taken in the morning follow-
ing an overnight fast and after a supine rest. After centri-
fugation, sera were collecte da n df r o z e na t- 7 0 ° Cu n t i l
analysis. Blood glucose levels were measured via a hexo-
kinase enzymatic reference method using a TBA-200FR
NEO biochemical analyzer (Toshiba, Tokyo, Japan) with
a coefficient of variation (CV) of 1.3%. Triglyceride levels
were measured via an enzymatic colorimetric method,
and HDL cholesterol was measured via a selective inhibi-
tion method using Hitachi 7600-210 and Hitachi 7180
biochemical analyzers (Hitachi, Tokyo, Japan) with CV of
3.0% for triglycerides and 5.0% for HDL cholesterol.
Plasma insulin levels were measured using an immunora-
diometric assay (Biosource, Nivelles, Belgium) with a CV
of 1.9%. The homeostasis model assessment for insulin
resistance (HOMA-IR) was used to estimate insulin resis-
tance as determined by the following formula: ((fasting
insulin (μU/mL) × fasting glucose (mmol/liter))/22.5
[24]. Serum estradiol was measured using an electroche-
miluminescence immunoassay analyzer (Roche Modular
Analytics E170; Roche, Mannheim, Germany) with a CV
of 2.4%. Serum adiponectin levels were measured using
an enzyme-linked immunosorbent assay (AdipoGen,
Seoul, Korea) with a CV of 3.5%. Serum leptin levels
were also assessed via enzyme-linked immunosorbent
assay (ALPCO Diagnostics, Salem, NH, USA) with a CV
of 4.6%.
Statistical analyses
The ER/PR status was classified into two categories.
Patients having ER-negative and PR-negative was desig-
nated as the ER/PR-negative group, and ER-positive or
PR-positive as the ER/PR-positive group. Because signifi-
cant interactions were observed between ER/PR status
and the primary measures, and because the use of adju-
vant endocrine therapy and prognosis varies according
to ER/PR receptor status, we analyzed data according to
ER/PR-positive or -negative receptor status.
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summarized as the mean ± standard deviation or per-
centage and compared using an unpaired t test or chi-
square statistic, as appropriate. If the distribution of a
continuous variable was skewed, median values and
interquartile ranges were presented, and the Wilcoxon-
Mann-Whitney test was used to detect significant
differences.
Owing to skewed distributions and the lack of consen-
sus on cut-off points for discriminating abnormalities,
leptin, adiponectin, insulin, HOMA-IR, and estradiol
concentrations were categorized as quartiles. These cate-
gorizations were defined based on the total sample. For
the purpose of illustration, estimates of time to breast
cancer recurrence stratified by the quartiles of these
variables were displayed using Kaplan-Meier curves. The
estimates were analyzed using the log-rank test for
trends.
The Cox proportional hazards regression model was
used to control for multiple factors simultaneously and
to estimate adjusted hazard ratios (HRs) and 95% confi-
dence intervals. The relative increase in the risk of
breast cancer recurrence for each of the three higher
quartiles was estimated in comparison to that for the
lowest quartile; it was also used to test for a linear trend
in the HRs across the quartiles. Participants receiving
medication for diabetes mellitus were excluded from the
insulin and HOMA-IR analyses because these drugs
may influence insulin secretion and/or insulin sensitiv-
ity. To adjust for possible confounding effects of prog-
nostic factors, we constructed two models. Model 1 was
constructed using variables with P < 0.25 in the univari-
ate analyses. Model 1 estimated HRs after adjusting for
age, alcohol consumption, BMI, regional lymph node
metastasis, tumor size, and chemotherapy. BMI was not
included as a covariate in the analyses of MetS. To eval-
uate the independent effects of adipokines and insulin
resistance, we constructed model 2 to adjust for the fac-
tors in model 1 plus HOMA-IR or adipokine levels, as
appropriate.
The proportional hazards assumption was assessed
graphically using log-log plots of all independent vari-
ables and statistically on the basis of Schoenfeld resi-
duals [25]. No major violations of the proportional
hazard assumption were detected. All analyses were per-
formed with Stata version 10.1 (StataCorp, College Sta-
tion, TX, USA). A two-sided P-value < 0.05 was
considered statistically significant.
Results
The median follow-up was 62.2 months (interquartile
range, 53.8 to 71.5 months) from the date of the initial
breast cancer surgery. In total, 94 patients experienced
recurrence: 48 cases (20.6%) were among 233 ER/PR-
negative patients and 46 cases (8.9%) were among 514
ER/PR-positive patients. The recurrence rate was 3.69
(cases per 1,000 person-months) for the ER/PR-negative
group and 1.44 for the ER/PR-positive group. All
patients with ER/PR-positive tumors received adjuvant
tamoxifen therapy. Histologically, 681 cases (91.2%)
were ductal carcinomas and 66 cases (8.8%) were of
other types (lobular, medullary, mucinous, papillary, or
tubular carcinoma).
Mean age at inclusion time was 45.9 ± 9.8 (mean ±
SD) years and 31.3% were postmenopausal women
(Table 1). Most baseline characteristics did not differ
between the ER/PR-negative and -positive groups (all Ps
> 0.05; Table 1, some data not shown). However, post-
menopausal women were more prevalent in the ER/PR-
negative group (P = 0.041), and significantly more
patients with ER/PR-negative tumors received che-
motherapy (P < 0.001). Serum adiponectin (P =0 . 0 0 4 )
and estradiol (P < 0.001) levels were higher in ER/PR-
positive patients, whereas serum leptin (P =0 . 0 3 9 )a n d
HOMA-IR (P = 0.013) values were lower. Serum insulin
concentrations did not differ between the groups (P =
0.179). The frequencies of MetS and its components
were distributed evenly between the two groups (all Ps
> 0.05), except for the frequency of elevated triglyceride
(P = 0.037), which was higher in the ER/PR-negative
group.
In the ER/PR-negative group, serum adiponectin con-
centrations showed an inverse association with breast
cancer recurrence according to the log-rank test for
trend (P for trend = 0.009; Figure 1). HOMA-IR values
showed a positive trend with borderline significance in
the ER/PR-negative group (P-value for trend = 0.078),
whereas insulin levels did not (P-value for trend =
0.450). Contrary to this finding, inverse associations for
HOMA-IR and insulin with cancer recurrence were
observed in the ER/PR-positive group with borderline
significance (P for trend = 0.096 and 0.078; Figure 2).
In the Cox proportional hazards regression analyses
adjusting for possible confounders, an inverse linear
trend was observed between serum adiponectin concen-
tration and breast cancer recurrence in the ER/PR-nega-
tive group (P for trend = 0.027 in model 1; Figure 3).
This association was further strengthened after adjust-
ment for the effects of insulin resistance (P for trend =
0.019 in model 2). Because the graphs are almost identi-
cal to each other, the graph for model 2 is not presented
in Figure 3. Adiponectin had no impact in the ER/PR-
positive group (P for trend = 0.779 in model 1 and 0.696
in model 2). HOMA-IR and insulin values showed
opposing effects according to ER/PR status. HOMA-IR
showed an increasing trend with borderline significance
in the ER/PR-negative group (P for trend = 0.087 in
model 1 and 0.114 in model 2) and a decreasing trend in
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Page 3 of 10Table 1 Characteristics of study participants, according to estrogen/progesterone receptor status*
Characteristic All
(N = 747)
ER/PR-negative†
(N = 233)
ER/PR-positive†
(N = 514)
P-value‡
Age (yr, mean ± SD) 45.9 ± 9.8 46.4 ± 10.6 45.7 ± 9.4 0.336
Current tobacco use (%) 3.6 3.4 3.7 0.858
Alcohol use above a safe level (%)
>0 and <7 g/week 6.4 7.3 6.0 0.771
>= 7 g/week 4.7 4.3 4.9
Postmenopausal (%) 31.3 36.5 29.0 0.041
Cancer size ≥ 2c m 21.6 22.3 21.2 0.732
Positive lymph nodes 39.6 38.6 40.1 0.707
Chemotherapy after surgery 76.0 87.1 71.0 <0.001
Adipokines and insulin resistance
Adiponectin, median (μg/ml, IQR)§ 5.9 (4.1 to 8.0) 5.2 (3.6 to 7.5) 6.1 (4.2 to 8.1) 0.004
1Q 187 68 119
2Q 187 78 109
3Q 187 35 152
4Q 186 52 134
Leptin, median (ng/ml, IQR)§ 6.0 (3.2 to 11.7) 7.8 (3.5 to 12.9) 5.8 (3.2 to 11.2) 0.039
1Q 187 53 134
2Q 187 45 142
3Q 187 67 20
4Q 186 68 118
HOMA-IR 1.7 (1.4 to 2.4) 1.9 (1.4 to 2.7) 1.7 (1.4 to 2.3) 0.013
1Q 187 52 135
2Q 187 49 138
3Q 186 60 126
4Q 187 72 115
Insulin (μU/ml, IQR)§ 6.7 (5.6 to 8.9) 7.0 (5.6 to 9.8) 6.6 (5.6 to 8.6) 0.179
1Q 189 63 126
2Q 185 44 141
3Q 186 57 129
4Q 187 69 118
Estradiol (pg/ml, IQR)§ 32.3 (14.3 to 89.5) 19.7 (12.7 to 67.2) 39.6 (15.9 to 96.8) <0.001
1Q 190 79 111
2Q 184 65 119
3Q 186 43 143
4Q 187 46 141
Components of metabolic syndrome
High blood pressure (%) ∥ 42.0 38.6 43.6 0.390
Obesity (%)¶ 33.7 36.5 32.5 0.179
Hyperglycemia (%)** 54.4 56.2 53.5 0.616
Decreased HDL cholesterol (%)†† 60.0 61.8 59.1 0.492
Elevated triglycerides (%)‡‡ 19.1 23.6 17.1 0.037
No. of components of metabolic syndrome (%)
1 25.4 20.2 27.8 0.170
2 29.3 30.9 28.6
≥3 35.9 39.1 34.4
* Plus-minus values are means ±SD.
† Estrogen Receptor (ER) and Progesterone Receptor (PR) status were classified as ER/PR-negative if ER-negative and PR-negative status, and ER/PR-positive if ER-
positive or PR-positive status.
‡ P-values are for the comparison between ER/PR-negative and ER/PR-positive status. § IQR denotes interquartile range (25th and 75th percentile)
∥High blood pressure was defined if systolic/diastolic blood pressure ≥130/85 mmHg or receiving drug treatment
¶ Obesity was defined if Body Mass Index ≥25 kg/m
2
** Hyperglycemia was defined if fasting glucose ≥100 mg/dl or receiving drug treatment
†† Decreased HDL cholesterol was defined if HDL cholesterol <50 mg/dl or receiving drug treatment
‡‡ Elevated triglycerides was defined if triglycerides ≥150 mg/dl or receiving drug treatment
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Page 4 of 10the ER/PR-positive group (P for trend = 0.081 in model 1
and 0.072 in model 2). Likewise, insulin showed an
inverse association with borderline significance in the
ER/PR-positive group (P for trend = 0.098 in model 1
a n d0 . 0 8 9i nm o d e l2 )b u tn o ti nt h eE R / P R - n e g a t i v e
group (P for trend = 0.486 in model 1 and 0.795 in
model 2). Estradiol (data not shown) and leptin did not
show any association in either model (P for trend > 0.05).
When patients with ER/PR-negative tumors had more
components of MetS, the risk of recurrence increased
significantly in model 1 (P for trend = 0.044; Table 2).
However, this association disappeared after adiponectin
and HOMA-IR were adjusted in model 2 (P for trend =
0.590). In terms of the association between each compo-
nent of MetS and recurrence, only fasting glucose level
in the ER/PR-positive group showed an inverse associa-
tion with recurrence (P = 0.020 in model 1 and 0.058 in
model 2).
Because of a possibility of bias from a remnant cancer
undetected in the initial evaluation, we tried additional
analyses after exclusion of recurrence cases within one
year. We found similar significant associations in the
additional Cox proportional hazards regression analyses
(data not shown). In ER/PR-negative patients, positive
trends were observed in adiponectin (P- value for trend
= 0.035 in model1, 0.020 in model2), HOMA-IR (P-
value for trend = 0.022 in model 1, 0.035 in model 2),
and metabolic syndrome (P-value for trend = 0.049 in
model 1, 0.691 in model 2). In ER/PR-positive patients,
adiponectin and metabolic syndrome did not show any
significant trends (all P for trend > 0.05) whereas
HOMA-IR (P-value for trend = 0.022 in model 1, 0.016
in model 2) and insulin (P-value for trend = 0.046 in
model 1, 0.036 in model 2) showed negative trends.
Discussion
Based on the relationship between obesity and breast
cancer [26], it was hypothesized that adipokines, which
are adipocyte-derived peptides, can influence breast can-
cer occurrence and recurrence. Of the adipokines, adi-
ponectin has drawn keen interest because it is inversely
associated with adiposity [27] and is a key regulator of
 
Figure 1 Kaplan-Meier cumulative recurrence curves for breast cancer patients in the estrogen receptor/progesterone receptor
negative group. The P-values for trend were calculated using the log-rank test for trend across the quartiles of adiponectin, leptin, HOMA-IR,
and insulin. The hatch marks on the curves indicate times when patients were censored.
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we demonstrated that serum adiponectin levels in ER/
PR-negative breast cancer showed an inverse relation-
ship with the risk of recurrence, and the lowest serum
quartile level of adiponectin showed a 2.82-fold (1.03 to
7.68) higher risk of recurrence compared to the highest
quartile. This association was significant even after
adjustment for possible mediating factors, including
BMI and HOMA-IR. This finding suggests that assessing
adiponectin concentrations may assist in establishing
prognosis in ER/PR-negative cancers regardless of obe-
sity and insulin resistance. We also speculate that inter-
ventions to increase serum adiponectin levels may
represent a therapeutic option for reducing recurrence
risk and improving prognosis in ER/PR-negative breast
cancer. Candidate interventions may include obesity
control; increased physical activity; and pharmacological
interventions such as PPAR-g agonists and others [29].
The mechanism underlying the observed association
between adiponectin and breast cancer is not well estab-
lished. However, insulin-sensitizing, anti-inflammatory,
anti-angiogenic, anti-proliferative, pro-apoptotic, and
antioxidant mechanisms have been mentioned as possi-
ble explanations for the anti-tumor effect of adiponectin
[30,31].
I na d d i t i o n ,i ti su n c l e a rw h yt h i sr e l a t i o n s h i pi so n l y
observed in ER/PR-negative cancer. Only four other
clinical studies have addressed this issue. One study
found a significant association in receptor-negative can-
cer [12], another in receptor-positive cancer [13], and
the remaining two showed no significant association
according to receptor status [8,14]. Because of the pau-
city of reliable evidence, clear explanations for this dis-
crepancy cannot be put forth. The present study
focused on cancer recurrence, and all ER/PR-positive
patients received adjuvant tamoxifen therapy. Although
data regarding the interaction between adiponectin and
estrogen are unavailable, there is evidence that estrogen
signaling pathways are interrelated with insulin and
some adipokines (leptin, tumor necrosis factor-a,a n d
interleukin-6) that have effects on adiponectin produc-
tion and action [32,33]. From these findings, we postu-
late that the anti-estrogenic effect of tamoxifen may
evoke a differential adiponectin-mediated effect in ER/
Figure 2 Kaplan-Meier cumulative recurrence curves for breast cancer patients in the estrogen receptor/progesterone receptor
positive group. The P-values for trend were calculated using the log-rank test for trend across the quartiles of adiponectin, leptin, HOMA-IR,
and insulin. The hatch marks on the curves indicate times when patients were censored.
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ponectin in ER/PR-positive breast cancer cannot be
excluded based only on the results of this study.
It is interesting to note that contrasting effects for
insulin resistance were observed in ER/PR-positive vs.
ER/PR-negative tumors (P for interaction = 0.021).
Unexpectedly, an inverse, marginally significant associa-
tion between insulin resistance and cancer recurrence
was observed in the ER/PR-positive group; this trend
was also observed in the analyses of serum insulin levels.
Furthermore, ER/PR-positive patients with hyperglyce-
mia showed decreased risk of recurrence (Table 2).
These findings support the notion of an inverse relation-
ship between insulin resistance and recurrence in ER/
PR-positive cancer. The mechanism and clinical signifi-
cance of these contrary effects are not clear. However,
the synergistic effect of estrogen with insulin/IGF-1 [33]
and the inverse association between insulin sensitivity
and tamoxifen use [34] may at least partly explain these
observations. Further study on this issue is required to
determine whether the observed effect is due to tamoxi-
fen use, random chance, or a true intrinsic characteristic
of ER/PR-positive breast cancer.
Our results regarding MetS are interesting in that the
significant association between MetS and recurrence in
ER/PR-negative tumors disappeared after adjustment for
HOMA-IR and adiponectin in model 2, suggesting that
insulin resistance and adipokines mediate the effects of
MetS.
This study has several limitations. First, cancer mortal-
ity risk was not analyzed because only 55 deaths
occurred (7.4% of patients). Second, the effect of human
epidermal growth factor receptor 2 status, another
important prognostic and predictive factor, was not con-
sidered because this parameter was not analyzed in 216
(28.9%) of the patients at recruitment. Third, we used
BMI rather than waist circumference to define obesity.
Fourth, firm conclusions on the associations of insulin
and HOMA-IR with breast cancer recurrences cannot
be drawn in the presence of decreased power due to
separate analyses by hormonal receptor status. Finally,
we did not analyze concentrations of high-molecular-
weight (HMW) adiponectin, which is the major source
of the active form of this protein [35]. We did not
attempt to measure this because the correlation between
total adiponectin and HMW adiponectin is high; a
recent study found that analyzing HMW adiponectin
produced similar results to total adiponectin and did
not offer any additional predictive value [10].
Menopausal status and diabetes medications are
another issue to be addressed. Because menopausal sta-
tus and age was highly correlated, we could not include
both covariates at the same statistical model simulta-
neously. But, when we analyzed the model including
(a) ER/PR-negative status                                   (b) ER/PR-positive status
Figure 3 Adjusted hazard ratio for breast cancer recurrence according to estrogen receptor/progesterone receptor status.C o x -
proportional regression was used for the estimation of hazard ratios with its 95% confidence intervals and P-value for trend. Hazard ratios were
adjusted for age (<40, 40 to 49, 50 to 59, or ≥60 years), alcohol consumption (none, 0.1 to 6.9, or ≥7.0 g/day), BMI (<23.0, 23.0 to 24.9, or
≥25 kg/m2), regional lymph node metastasis (negative or positive), tumor size (<2 cm or ≥2 cm), and chemotherapy (yes or no).
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conclusions with the model including age. Nineteen
patients were receiving diabetes medication, which
could influence blood levels of insulin, glucose, and adi-
ponectin concentration in this study. We tried addi-
tional analyses with the exclusion of these patients. And
we found similar results with the model including dia-
betes medication.
This study has several strengths. For example, it high-
lights temporal-causal relationships. In addition, a num-
ber of factors related to obesity and insulin resistance
were examined. To our knowledge, this is the first study
investigating the complicated effects of obesity, insulin
resistance, adipokines, and MetS on the prognosis of
breast cancer. Our findings suggest the clinical useful-
ness of assessing adiponectin, insulin resistance, and
metabolic abnormalities in predicting prognosis. The
fact that these parameters showed significant associa-
tions with ER/PR-negative cancer may assist in the
development of new treatment options; improving treat-
ment for these individuals is critical because of the gen-
erally poorer prognosis of ER/PR-negative cancer and
the inapplicability of adjuvant endocrine therapy.
Conclusions
This study suggests that measuring serum adiponectin
levels and HOMA-IR values has clinical significance in
predicting prognosis, and interventions for increasing
serum adiponectin level and decreasing insulin resis-
tance may protect against recurrence in ER/PR-negative
breast cancer. MetS may also be used to predict prog-
nosis, but this association seems to be mediated by insu-
lin resistance or adipokines. Note that we cannot extend
our conclusions to include ER/PR-positive cancer, possi-
bly because of the anti-estrogenic effect of adjuvant
endocrine therapy and other possible confounders.
Further studies on this issue are needed especially in the
ER/PR-positive cancer.
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No. of components of metabolic syndrome
0 Reference Reference Reference Reference
1 0.81 (0.22 to 2.90) 0.57 (0.15 to 2.15) 2.99 (0.69 to 12.96) 2.28 (0.51 to 10.12)
2 1.09 (0.35 to 3.39) 0.044†† 0.67 (0.20 to 2.24) 0.590†† 1.68 (0.36 to 7.75) 0.575†† 1.85 (0.39 to 8.68) 0.800††
≥3 1.95 (0.66 to 5.71) 0.96 (0.29 to 3.18) 1.72 (0.37 to 7.99) 1.95 (0.40 to 9.48)
*In model 1, hazard ratios were calculated with the use of Cox regression after adjustment for age (<40, 40 to 49, 50 to 59, or ≥60 years), alcohol consumption
(none, 0.1 to 6.9, or ≥7.0 g/day), regional lymph node metastasis (negative or positive), tumor size (<2 cm or ≥2 cm), and chemotherapy (yes or no).
†Model 2 was adjusted for the factors in Model 1 plus adiponectin and HOMA-IR.
‡High blood pressure was defined if systolic/diastolic blood pressure ≥130/85 mmHg or receiving drug treatment.
§Obesity was defined if Body Mass Index ≥25 kg/m
2.
∥Hyperglycemia was defined as fasting glucose ≥100 mg/dl or receiving drug treatment.
¶Decreased HDL cholesterol as defined if HDL cholesterol <50 mg/dl or receiving drug treatment.
**Elevated triglycerides was defined if triglycerides ≥150 mg/dl or receiving drug treatment.
††P-value for trend was calculated to check the trend of the hazard ratio for breast cancer recurrence according to the number of components of metabolic
syndrome.
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